ADHD

The treatment is the first liquid non-stimulant for attention deficit hyperactivity disorder to be approved in the United States.

There have been ongoing concerns about the long-term effects of prenatal exposure on neurodevelopment.

Chemotherapy, medication for attention deficit/hyperactivity disorder, glucagon-like peptide-1 agonists for weight loss and diabetes, and local anesthetics were among the drugs most affected by shortages.

Although approximately 95% of online drug sellers operate illegally, many consumers may never know the medications they receive are not what they claim to be.

An increased demand for methylphenidate products as a result of Adderall shortages has led to a short supply of some popular products, including Ritalin and Concerta.

Cases highlight patients who have attention-deficity/hyperactivity disorder and diabetic peripheral nephropathy.

Teva is unable to meet demand for dextroamphetamine/amphetamine, and other companies struggle to keep up.

Pharmacists are crucial in supporting patients with attention-deficit hyperactivity disorder as shortages of Adderall continue.

Although attention-deficit/hyperactivity disorder (ADHD) is not as common in adults, it can still be present and bothersome, however, adults with ADHD may have learned to hide it a bit better than children.

There is a lack of funding for attention-deficit hyperactivity disorder and coinciding psychological research compared to the funds generated for autism research.

Study does not show a statistically significant association for specific cardiovascular outcomes related to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction associated with medications for attention-deficit hyperactivity disorder.

Viloxazine ER treatment was associated with symptom, function, and clinical improvement in adults with attention-deficit hyperactivity disorder.

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.

Viloxazine extended-release capsules are indicated as a once-daily, flexible-dose nonstimulant drug for attention-deficit hyperactivity disorder.

Analysis indicates that factors associated with psychological flourishing include being married and physically active, as well as free from chronic pain and anxiety and depression.

ADHD is a mental health disorder that includes a combination of persistent challenges, such as difficulty paying attention, hyperactivity, and impulsive behavior.

In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with ADHD.

Misconceptions about the diagnosis of attention-deficit hyperactivity disorder reduce the credibility of health care providers and delay or prevent treatment for patients suffering from this condition.

Quiz questions to assess your knowledge on common symptoms and treatments for attention-deficit hyperactivity disorder.

ADHD Awareness Months brings attention to a common, but still somewhat misunderstood condition that pharmacists encounter on a near daily basis.

But the good news is treatments can be tailored for patients with the chronic behavioral condition.

There are many substances that are included on the prohibited list for the Tokyo Olympics that are considered standard medications for certain disease states.

Alterations in the amino acid profile of children with attention-deficit hyperactivity disorder may support further research into potential new treatment strategies.

It is currently debated whether or not sluggish cognitive tempo—defined as a collection of symptoms that include persistent dreaminess, fatigue, and slow working speed—is part of ADHD or separate from it.

Study indicates that the genetics affecting aggression in children with attention-deficit hyperactivity disorder and disruptive behavior disorders are the same as genetics underlying aggression in the general population.

The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.

The amount of green space surrounding children’s homes may impact the development of ADHD.

The strongest associations with attention-deficit hyperactivity disorder were present for nervous system, respiratory, musculoskeletal, and metabolic diseases.

Although ADHD is generally treated through medication and/or behavioral treatments, in more than 25% of children, these treatments alone are insufficient.

Study suggests attention-deficit hyperactivity disorder medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.